Skip to main content
S&P 5007,722.60+0.60%DOW52,377.57+0.03%NASDAQ26,477.81+1.18%BTC$80,652.00+0.63%ETH$2,343.36+0.75%GOLD$4,075.00+0.01%OIL$100.37+0.47%
Smart Investors Daily
SID Premium
AM

NASDAQ · AMRX

Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$21.44

Up+$0.42 (+2.00%)

Updated Oct 27, 2026, 11:22 PM

SID Score

5.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.34B
P/E ratio
60.06
Dividend yield
0.00%
52-week range
$9.99 – $21.46
Volume
2.89M
Avg. volume
2.49M

Price performance · AMRX

AMRX price history

1M range · 22 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

AMRX closed at $21.44 after 22 trading sessions, up 4.59% for the selected period.

Last close
$21.44
Period change
+4.59%
Period low
$18.90
Period high
$21.44
Daily close
View OHLC price history
AMRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$20.93$21.46$20.93$21.442.89M
Oct 26, 2026$20.63$21.14$20.5435$21.024.95M
Oct 23, 2026$20.45$20.49$19.9301$20.384.93M
Oct 22, 2026$20.32$20.579$20.205$20.486.04M
Oct 21, 2026$19.90$20.30$19.7302$20.204.66M
Oct 20, 2026$19.51$19.91$19.31$19.846.82M
Oct 19, 2026$19.10$19.445$18.95$19.362.1M
Oct 16, 2026$19.28$19.385$18.94$19.182.43M
Oct 15, 2026$18.96$19.78$18.785$19.254.45M
Oct 14, 2026$19.49$19.93$18.855$18.903.96M
Oct 13, 2026$20.045$20.15$19.45$19.575M
Oct 12, 2026$20.04$20.28$19.86$20.034.59M
Oct 9, 2026$19.59$19.93$19.5265$19.912.09M
Oct 8, 2026$19.65$19.715$18.97$19.653.24M
Oct 7, 2026$20.24$20.53$19.53$19.654.66M
Oct 6, 2026$20.53$20.60$20.00$20.2953.59M
Oct 5, 2026$20.43$20.59$20.23$20.353.91M
Oct 2, 2026$20.19$20.54$19.995$20.302.82M
Oct 1, 2026$20.13$20.26$19.61$20.073.94M
Sep 30, 2026$20.29$20.4999$19.98$20.144.1M
Sep 29, 2026$20.43$20.78$20.06$20.202.85M
Sep 28, 2026$19.55$20.625$19.425$20.502.99M

Latest AMRX news

The latest Smart Investors Daily articles mentioning AMRX.

Stock researchCompany · Overview

AMRX research

Overview

Company profile and research snapshot.

Company profile

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
AMRX recent ratings
DateFirmRatingTarget
Oct 22, 2026JP MorganOverweight—
Sep 23, 2026OppenheimerOutperform—
Sep 17, 2026BarclaysOverweight—
Sep 9, 2026Leerink PartnersOutperform—
Aug 26, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Amneal Pharmaceuticals (AMRX) Faces A Valuation Test Following Slowing Growth Concerns

Amneal Pharmaceuticals (AMRX) is back in focus after commentary highlighting slowing sales growth, softer earnings per share trends, and weaker returns on capital that point to execution challenges inside the business. The recent commentary comes after a powerful run in the stock. Amneal Pharmaceuticals has posted a year to date share price return of 60.98% and a 1 year total shareholder return of 93.18%, while the 3 year total shareholder return is more than four times the starting capital...

Yahoo · Oct 22, 2026

1 Russell 2000 Stock with Competitive Advantages and 2 Facing Challenges

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By